Amgen Inc. stock (US0311621009): EU approval for IMDYLLTRA adds fresh catalyst

Amgen Inc. shares on Nasdaq remained in focus after the European Commission approved the companys immunotherapy IMDYLLTRA for extensive-stage small cell lung cancer, providing a new regulatory milestone alongside the latest quarterly figures.

Amgen Inc. shares traded around USD 336 on Nasdaq under the ticker AMGN at the start of the week, keeping the United States-based biotechnology group in the spotlight after the European Commission granted marketing authorization for its oncology therapy IMDYLLTRA for extensive-stage small cell lung cancer, adding a fresh regulatory catalyst to the stock, according to a company press release on 05/30/2026 and coverage by PR Newswire and MarketScreener as of 05/31/2026.

The approval in the European Union is based on the Phase 3 DeLLphi-304 trial, in which IMDYLLTRA reduced the risk of death by 40% compared with standard chemotherapy in patients with extensive-stage small cell lung cancer, according to the Amgen announcement on 05/30/2026 and a corresponding PR Newswire report as of the same date.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology and biopharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology, inflammation, bone health and cardiovascular therapies, including legacy blockbusters and newer biologics
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen positions itself as a large-cap biotechnology player that discovers, develops and commercializes human therapeutics, with revenue primarily generated from biologic and targeted drugs addressing oncology, inflammatory diseases, bone disorders and cardiometabolic conditions.

Latest quarterly results for Amgen Inc. at a glance

For the first quarter of 2026, Amgen reported group revenue of USD 8.85 billion and GAAP diluted earnings per share of USD 4.02, according to the companys quarterly report filed with the U.S. Securities and Exchange Commission on 04/25/2026 and detailed on its investor relations website as of that date.

In the same Q1 2026 filing on 04/25/2026, Amgen stated that product sales were driven by oncology and inflammation brands, while the company reiterated its full-year 2026 guidance ranges for revenue and adjusted earnings per share, according to the SEC submission and the related investor presentation as of 04/25/2026.

Conclusion

The European Commission approval of IMDYLLTRA for extensive-stage small cell lung cancer provides Amgen Inc. with an additional oncology asset in the European Union, complementing its existing portfolio of biologics and targeted therapies. The Q1 2026 numbers confirm that oncology and inflammation products remain central to the groups top-line performance, while the reiterated full-year guidance highlights managements current expectations for the business trajectory.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.